Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-30
2005-08-30
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S275000, C544S122000, C544S296000, C544S323000
Reexamination Certificate
active
06936607
ABSTRACT:
This invention is directed to pyrimidine derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.
REFERENCES:
patent: 4946956 (1990-08-01), Wheeler et al.
patent: 5017466 (1991-05-01), Kobayashi et al.
patent: 2003/0078271 (2003-04-01), Blackburn et al.
patent: 2004/0127502 (2004-07-01), Blackburn et al.
patent: 1477349 (1977-06-01), None
patent: 11-158073 (1999-06-01), None
patent: WO02060392 (2002-08-01), None
Kinney et al., Galanin Receptor-Mediated Inhibition of Glutamate Release in the Arcuate Nucleus of the Hypothalamus, The Journal of Neuroscience, May 15, 1998, 18(10: 3489-3500.
H. Lunobeck A/S
Kalinchak Stephen G.
Rao Deepak
LandOfFree
2,4,6-Triaminopyrimidines for the treatment of depression... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,4,6-Triaminopyrimidines for the treatment of depression..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4,6-Triaminopyrimidines for the treatment of depression... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474495